Why Pacira (PCRX) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Should You Buy Pacira (PCRX) After Golden Cross?
After reaching an important support level, Pacira BioSciences, Inc. (PCRX) could be a good stock pick from a technical perspective. PCRX recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Why Pacira (PCRX) Could Beat Earnings Estimates Again
Pacira (PCRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Pacira BioSciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your Rights - PCRX
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Contact Levi & Korsinsky by March 14, 2025 Deadline to Join Class Action Against Pacira BioSciences, Inc.(PCRX)
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Shareholders that lost money on Pacira BioSciences, Inc.(PCRX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 14, 2025 in Pacira Lawsuit - PCRX
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against Pacira BioSciences Inc
LOS ANGELES, CA / ACCESSWIRE / January 15, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pacira BioSciences, Inc. ("Pacira" or "the Company") (NASDAQ:PCRX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 2, 2023 to August 8, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before March 14, 2025.
Pacira BioSciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your Rights - PCRX
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
PCRX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Pacira BioSciences, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / January 15, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Pacira BioSciences, Inc. ("Pacira" or "the Company") (NASDAQ:PCRX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Pacira securities between August 2, 2023 and August 8, 2024, both dates inclusive (the "Class Period").
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Pacira BioSciences, Inc.(PCRX) Shareholders
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Levi & Korsinsky Notifies Pacira BioSciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - PCRX
NEW YORK, NY / ACCESSWIRE / January 14, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
